Clarity Pharmaceuticals Ltd (CU6.AX) stock: key figures, P/E, revenue and dividend

Health Care · Australia · ISIN AU0000165375

Price
1.66 AUD
Market cap
618.68 m AUD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-57.49 %
Return on assets (ROA)
-53.75 %

Clarity Pharmaceuticals Ltd financials

Fiscal year20252026
Revenue9.00 m AUD0.00 AUD
Gross profit9.00 m AUD0.00 AUD
EBIT-69.00 m AUD-118.00 m AUD
Net income-64.00 m AUD-107.00 m AUD
Diluted EPS – continuing operations-0.18 AUD-0.29 AUD

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.